INNO · INNOCAN PHARMA Corp

We are a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceutical segment, we develop innovative drug delivery technologies for both human and animal health applications, based on advanced cannabinoids science, to treat various conditions to improve quality of life. Supported by pre-clinical studies conducted in various animal models, but not yet verified in humans, our synthetic Cannabidiol-loaded Liposome injection Platform (LPT-CBD) facilitates exact dosing and the prolonged and controlled release of synthetic cannabidiol, or CBD, into the blood stream. While determinations of safety and efficacy are solely within the authority of the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory bodies, we expect, based on various scientific studies, including a report of the World Health Organization, that cannabidiol in general will avoid many of the risks of addiction, tolerance, and dependency, commonly associated with opioids. To date, we have not yet submitted an IND or commenced clinical trials for our LPT-CBD product candidate. However, our LPT-CBD is in late pre-clinical stage of devel…

F-1/A · 2026-04-03 · 0001493152-26-015152

Company description from the cited filing.